Olsson, Henrik http://orcid.org/0000-0002-2270-2017
Kartasalo, Kimmo http://orcid.org/0000-0002-9470-4783
Mulliqi, Nita
Capuccini, Marco
Ruusuvuori, Pekka
Samaratunga, Hemamali
Delahunt, Brett
Lindskog, Cecilia http://orcid.org/0000-0001-5611-1015
Janssen, Emiel A. M.
Blilie, Anders
Egevad, Lars
Spjuth, Ola http://orcid.org/0000-0002-8083-2864
Eklund, Martin http://orcid.org/0000-0001-5032-5266
,
Funding for this research was provided by:
David och Astrid Hageléns Stiftelse
Orionin Tutkimussäätiö
KAUTE-Säätiö
Oskar Huttunen Foundation
Vetenskapsrådet (2020-00692)
Cancerfonden (21 1715 Pj)
Magnus Bergvalls Stiftelse
Region Stockholm, Svenska Druidorden, Åke Wibergs Stiftelse, Swedish e-Science Research Center (SeRC), the Swedish Prostate Cancer Foundation
Article History
Received: 2 May 2022
Accepted: 8 November 2022
First Online: 15 December 2022
Competing interests
: M.E. has four patents (WO2013EP74259 20131120, WO2013EP74270 20131120, WO2018EP52473 20180201, and WO2013SE50554 20130516) related to prostate cancer diagnostics pending, and has patent applications licensed to Thermo Fisher Scientific, and is named on a pending patent (1900061-1) related to cancer diagnostics quality control. All other authors declare no competing interests. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.